Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Buy” by Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned an average recommendation of “Buy” from the seven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $18.08.

ROIV has been the subject of several analyst reports. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $10.71 on Wednesday. Roivant Sciences has a 1-year low of $9.76 and a 1-year high of $13.06. The company has a market cap of $7.64 billion, a P/E ratio of -71.40 and a beta of 1.26. The stock has a 50-day moving average of $10.78 and a two-hundred day moving average of $11.48.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, analysts anticipate that Roivant Sciences will post -0.92 EPS for the current fiscal year.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 218,041 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the sale, the chief operating officer now owns 896,869 shares of the company’s stock, valued at $9,345,374.98. The trade was a 19.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CIO Mayukh Sukhatme sold 185,946 shares of the business’s stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total value of $2,231,352.00. Following the completion of the sale, the executive now directly owns 18,836,547 shares in the company, valued at $226,038,564. This represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,975,586 shares of company stock worth $22,640,661. 7.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Roivant Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Treasurer of the State of North Carolina grew its position in Roivant Sciences by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company’s stock worth $2,213,000 after purchasing an additional 1,170 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Roivant Sciences by 1.5% in the fourth quarter. WINTON GROUP Ltd now owns 92,526 shares of the company’s stock worth $1,095,000 after acquiring an additional 1,332 shares during the last quarter. Covestor Ltd raised its stake in shares of Roivant Sciences by 7.5% in the fourth quarter. Covestor Ltd now owns 20,634 shares of the company’s stock worth $245,000 after acquiring an additional 1,444 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after buying an additional 1,507 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.